Sheraton Seattle Hotel Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2014
Here are the related meetings in 2021:
Innovative Vaccine Approaches (Z5)
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
The Modes of Action of Vaccine Adjuvants (S1)
Organizer(s) Philippa C. Marrack, Steven Reed and Robert A. Seder
October 8—13, 2014
Sheraton Seattle Hotel • Seattle, Washington USA
Discounted Abstract Deadline: Jun 10, 2014
Abstract Deadline: Jul 8, 2014
Scholarship Deadline: Jun 10, 2014
Discounted Registration Deadline: Aug 7, 2014
Sponsored by Pfizer Inc. Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation.
Summary of Meeting:
Globally, vaccines are the most effective medical interventions in limiting morbidity and mortality against infections. Effective vaccines are administered in a variety of formulations and include not only portions of their target but also adjuvants. Adjuvants can improve the magnitude and breadth of the immune response and immunological memory against the target and also determine the nature of the generated immune response. Almost all vaccines that are now in use include adjuvants, such as nucleic acids from the target organisms, in the case of attenuated virus vaccines, insoluble aluminum salts (alum), oil-in-water emulsions (MF-59) or formulated toll-like receptor ligands (MPL-TLR4). However, the world still lacks consistently effective vaccines against many infectious agents, tuberculosis, malaria and HIV and against cancers. Therefore much current research is devoted to identification of newer adjuvants, adjuvants that will safely induce the type of immune response that will most effectively deal with its target. In many cases the precise mode of action of the adjuvant is not known. For example the mode of action of alum, an adjuvant that has been used in vaccines since the 1930s and generates excellent antibody responses, is still inadequately understood. This conference will focus on the cell and molecular mechanisms of action of old and new adjuvants and other immunomodulatory agents and their use in various vaccines against infectious diseases and cancer.
View Scholarships/Awards
Globally, vaccines are the most effective medical interventions in limiting morbidity and mortality against infections. Effective vaccines are administered in a variety of formulations and include not only portions of their target but also adjuvants. Adjuvants can improve the magnitude and breadth of the immune response and immunological memory against the target and also determine the nature of the generated immune response. Almost all vaccines that are now in use include adjuvants, such as nucleic acids from the target organisms, in the case of attenuated virus vaccines, insoluble aluminum salts (alum), oil-in-water emulsions (MF-59) or formulated toll-like receptor ligands (MPL-TLR4). However, the world still lacks consistently effective vaccines against many infectious agents, tuberculosis, malaria and HIV and against cancers. Therefore much current research is devoted to identification of newer adjuvants, adjuvants that will safely induce the type of immune response that will most effectively deal with its target. In many cases the precise mode of action of the adjuvant is not known. For example the mode of action of alum, an adjuvant that has been used in vaccines since the 1930s and generates excellent antibody responses, is still inadequately understood. This conference will focus on the cell and molecular mechanisms of action of old and new adjuvants and other immunomodulatory agents and their use in various vaccines against infectious diseases and cancer.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
WEDNESDAY, OCTOBER 8
THURSDAY, OCTOBER 9
FRIDAY, OCTOBER 10
SATURDAY, OCTOBER 11
SUNDAY, OCTOBER 12
MONDAY, OCTOBER 13
Conference Program Print | View meeting in 12 hr (am/pm) time
WEDNESDAY, OCTOBER 8
14:00—19:30
Keystone Symposia: Arrival and Registration
16:00—17:00
Grand Challenges & Keystone Symposia Joint Scientific Session: Innovation Panel Plenary
* Sue Desmond-Hellman, CEO of the Bill & Melinda Gates Foundation
• Francis Collins, Director, National Institutes of Health
• Bill Gates, Co-Chair of the Bill & Melinda Gates Foundation
• Arunachalam Muruganantham, Founder of Jayaashree Industries
• Amy Smith, Founder and Co-Director, D-Lab, Massachusetts Institute of Technology
* Sue Desmond-Hellman, CEO of the Bill & Melinda Gates Foundation
• Francis Collins, Director, National Institutes of Health
• Bill Gates, Co-Chair of the Bill & Melinda Gates Foundation
• Arunachalam Muruganantham, Founder of Jayaashree Industries
• Amy Smith, Founder and Co-Director, D-Lab, Massachusetts Institute of Technology
08:30—11:30
Cell Death and Nucleic Acids as Adjuvants
To understand how nucleic acids and other components of the host act as immunological adjuvants.
*
Emilio Flano,
Seres Therapeutics, USA
Ken J. Ishii,
National Institute of Biomedical Innovation, Health and Nutrition, Japan
Nucleic Acids as "Built-in" or "Inducible" Adjuvant during Vaccination
Nucleic Acids as "Built-in" or "Inducible" Adjuvant during Vaccination
Anna Marie Pyle,
Yale University, USA
Small RIG-I Ligands and their Development as Antivirals and Vaccine Adjuvants
Small RIG-I Ligands and their Development as Antivirals and Vaccine Adjuvants
Thomas W. Dubensky, Jr.,
Tempest Therapeutics, USA
Development of Human STING-Activating Synthetic Cyclic Dinucleotide Derivatives as Adjuvants for Cancer Immunotherapy and Infectious Disease
Development of Human STING-Activating Synthetic Cyclic Dinucleotide Derivatives as Adjuvants for Cancer Immunotherapy and Infectious Disease
Robert E. Johnston,
Global Vaccines, Inc., USA
Short Talk: Biological Adjuvant Activity of Alphavirus Replicon Particles
Short Talk: Biological Adjuvant Activity of Alphavirus Replicon Particles
14:30—16:30
Workshop 1: TLRs and STING
*
Robert R. Kane,
Baylor University, USA
Synthesis and Protein Conjugation of TLR Agonists
Synthesis and Protein Conjugation of TLR Agonists
Aideen C. Allen,
Institut de Pharmacologie et de Biologie Structurale, France
A Novel TLR2 Agonist from B. pertussis Is a more Effective Adjuvant than Alum for an Acellular Pertussis Vaccine
A Novel TLR2 Agonist from B. pertussis Is a more Effective Adjuvant than Alum for an Acellular Pertussis Vaccine
Roger H. Brookes,
Sanofi Pasteur, Canada
Dose-Ranging Analysis of H4 TB Vaccine Formulations in Mouse and Fresh Human Whole Blood Reveal that an Excess of IC31® Adjuvant Is Needed for Immunomodulation
Dose-Ranging Analysis of H4 TB Vaccine Formulations in Mouse and Fresh Human Whole Blood Reveal that an Excess of IC31® Adjuvant Is Needed for Immunomodulation
Mark T. Orr,
Infectious Disease Research Institute, USA
Mechanistic Insights Into the TH1 Induction Capacity of Formulated TLR4 Agonist Adjuvants
Mechanistic Insights Into the TH1 Induction Capacity of Formulated TLR4 Agonist Adjuvants
Caroline Junqueira,
Centro de Pesquisas René Rachou/ Fiocruz, Brazil
Attenuated Trypanosoma cruzi Expressing Tumor Antigen to Induce a Potent Antitumor Immunity Mediated by TLRs Agonists
Attenuated Trypanosoma cruzi Expressing Tumor Antigen to Induce a Potent Antitumor Immunity Mediated by TLRs Agonists
Andres Sanchez Alberti,
Universidad de Buenos Aires - CONICET, Argentina
Sting Agonist and Antigen Design as a Vaccine Model to Combat Parasitic Chronic Infections
Sting Agonist and Antigen Design as a Vaccine Model to Combat Parasitic Chronic Infections
*
Yueh-Ming Loo,
AstraZeneca, USA
Small Molecule RIG-I Agonists as Vaccine Adjuvants
Small Molecule RIG-I Agonists as Vaccine Adjuvants
Shan Lu,
University of Massachusetts Medical Center, USA
Involvement of Aim2 Inflammasome Pathway in Antigen Specific Antibody Responses Elicited by HA-Expressing Influenza DNA Vaccine
Involvement of Aim2 Inflammasome Pathway in Antigen Specific Antibody Responses Elicited by HA-Expressing Influenza DNA Vaccine
14:30—16:30
Workshop 2: T Cells
*
Nancy A. Hosken,
University of Washington, USA
Alicja Misiak,
Trinity College Dublin, Ireland
Lung gammadelta T Cells Mount Innate and Adaptive Immune Responses to Bordetella pertussis – Implications for Pertussis Vaccines
Lung gammadelta T Cells Mount Innate and Adaptive Immune Responses to Bordetella pertussis – Implications for Pertussis Vaccines
Chiung-Yu Hung,
University of Texas at San Antonio, USA
Th17 Immunity is Essential for Optimal Protection Against Coccidioides Infection
Th17 Immunity is Essential for Optimal Protection Against Coccidioides Infection
*
Stephen M. Carpenter,
Regeneron Pharmaceuticals, USA
Heavily-Armed but Outnumbered: A Selective Loss of Memory CD8+ T Cells during Tuberculosis may Eclipse the Benefit of Vaccination
Heavily-Armed but Outnumbered: A Selective Loss of Memory CD8+ T Cells during Tuberculosis may Eclipse the Benefit of Vaccination
Dipendra Kumar Mitra,
All India Institute of Medical Sciences - AIIMS, India
Programed Death Receptor-1 Preferentially Inhibits Poly-Functional T Cells in Human Tuberculosis
Programed Death Receptor-1 Preferentially Inhibits Poly-Functional T Cells in Human Tuberculosis
Yasser A. Aldhamen,
Michigan State University, USA
Therapeutic Blockade of CRACC, a Novel Immune Modulation Strategy for Enhancing Memory T Cell Immune Responses
Therapeutic Blockade of CRACC, a Novel Immune Modulation Strategy for Enhancing Memory T Cell Immune Responses
Robert Weinkove,
Capital & Coast District Health Board, New Zealand
Glycolipid-Peptide Conjugates Exploit Natural Killer T Cells to Enhance Peptide-Specific CD8+ T Cell Responses
Glycolipid-Peptide Conjugates Exploit Natural Killer T Cells to Enhance Peptide-Specific CD8+ T Cell Responses
17:00—19:00
The Action of Adjuvants on Dendritic Cell Subsets
To learn about the use of adjuvants, alone, or in combination with biologicals, in cancer vaccines.
*
Jonathan A. Deane,
Kumquat Biosciences, USA
Ofer Levy,
Boston Children's Hospital, USA
In vitro Modeling to Inform Age-Specific Adjuvanted Vaccine Development
In vitro Modeling to Inform Age-Specific Adjuvanted Vaccine Development
Claudia Jakubzick,
Dartmouth College, USA
Short Talk: Dendritic Cell Subsets Require cis-Activation for Cytotoxic CD8 T Cell Induction
Short Talk: Dendritic Cell Subsets Require cis-Activation for Cytotoxic CD8 T Cell Induction
Karin Loré,
Karolinska Institutet, Sweden
Innate Immune Activation in vivo after Adjuvant Administration
Innate Immune Activation in vivo after Adjuvant Administration
08:30—11:45
Immunostimulatory Properties of Particles
Particles have long been known to have immunostimulatory properties. This session will discuss the mechanisms by which particles have this effect.
*
Rima L. McLeod,
University of Illinois, USA
Tarek M. Fahmy,
Yale University, USA
Modular Nanomaterials Orchestrating the Direction and Magnitude of the Immune Response
Modular Nanomaterials Orchestrating the Direction and Magnitude of the Immune Response
Gary J. Nabel,
Sanofi, USA
Synthetic Nanoparticle and Virus-Like Particle Vaccines for Influenza and Alphaviruses: Developing New Technologies to Address Growing Public Health Concerns
Synthetic Nanoparticle and Virus-Like Particle Vaccines for Influenza and Alphaviruses: Developing New Technologies to Address Growing Public Health Concerns
James I. Andorko,
University of Maryland, USA
Short Talk: Intrinsic Immunogenicity of Rapidly Degradable Polycations: Role of Physicochemical Properties
Short Talk: Intrinsic Immunogenicity of Rapidly Degradable Polycations: Role of Physicochemical Properties
Marcela Rincon-Restrepo,
École Polytechnique Fédérale de Lausanne, Switzerland
Short Talk: Polymersomes Enhance the Induction of Follicular Helper CD4 T Cells and Promote Long Antibody Responses
Short Talk: Polymersomes Enhance the Induction of Follicular Helper CD4 T Cells and Promote Long Antibody Responses
Darrell J. Irvine,
Massachusetts Institute of Technology, USA
Controlling Immunization Potency and Safety through Molecular Targeting of Vaccines to Lymph Nodes
Controlling Immunization Potency and Safety through Molecular Targeting of Vaccines to Lymph Nodes
Steven Reed,
Infectious Disease Research Institute, USA
Status and Clinical Development of Next Generation of TLR 4 Based Adjuvants
Status and Clinical Development of Next Generation of TLR 4 Based Adjuvants
14:30—16:30
Workshop on Adjuvant Formulation
Session to cover three case studies on adjuvant formulation. Co-sponsored by the Global HIV Vaccine Enterprise, the Bill &Melinda Gates Foundation and the Division of AIDS, National Institute of Allergy Infectious Diseases, National Institutes of Health.
17:00—19:00
Lipids, Emulsions and Detergents
To understand the ways in which these unexpected materials improve immune responses.
*
Christopher B. Fox,
Infectious Disease Research Institute, USA
Yan Shi,
University of Calgary, Canada
Redirecting MHC Class II Antigen for MHC Class I Crosspresentation during Phagocytosis
Redirecting MHC Class II Antigen for MHC Class I Crosspresentation during Phagocytosis
Anja Seubert,
GlaxoSmithKline, Italy
The Mechanism of Action of the Oil-in-Water Adjuvant MF59
The Mechanism of Action of the Oil-in-Water Adjuvant MF59
Eugene Maraskovsky,
CSL Limited, Australia
Mechanism of Action for Induction of Innate and Adaptive Immune Responses using ISCOMATRIX® Adjuvant
Mechanism of Action for Induction of Innate and Adaptive Immune Responses using ISCOMATRIX® Adjuvant
Anthony L. Desbien,
Aduro Biotech, USA
Short Talk: A Role for the Inflammasome during Immunization with the TLR4 Agonist GLA when Combined with a Squalene Emulsion
Short Talk: A Role for the Inflammasome during Immunization with the TLR4 Agonist GLA when Combined with a Squalene Emulsion
08:30—11:30
Human Genetics and Adjuvants
The genetic make up of individuals affects their reponses to vaccines. This issue will be discussed here.
*
Angelika Riemer,
German Cancer Research Center /DKFZ, Germany
Jean-Laurent Casanova,
Rockefeller University, USA
Toward a Genetic Theory of Childhood Infectious Diseases
Toward a Genetic Theory of Childhood Infectious Diseases
Rafick Sekaly,
Case Western Reserve University, USA
Predictors of Adjuvant and Vaccine Efficacy
Predictors of Adjuvant and Vaccine Efficacy
Emmanuel Mignot,
Stanford University School of Medicine, USA
Narcolepsy, Vaccination and Immunogenetics
Narcolepsy, Vaccination and Immunogenetics
Robert L. Coffman,
Dynavax Technologies, USA
Systems Biology Analysis of the Human Response to Hepatitis B Vaccines using Alum or CpG Oligonucleotide Adjuvants
Systems Biology Analysis of the Human Response to Hepatitis B Vaccines using Alum or CpG Oligonucleotide Adjuvants
Taiki Aoshi,
National Institute of Biomedical Innovation, Japan
Short Talk: Adjuvant Database Project: Comprehensive Transcriptome Analysis in Animal Models
Short Talk: Adjuvant Database Project: Comprehensive Transcriptome Analysis in Animal Models
14:30—16:30
Workshop 3: VLPs and Antigen Presentation
*
Darrell J. Irvine,
Massachusetts Institute of Technology, USA
Rajesh Kumar,
Tulane University, USA
Plasmodium falciparum Pfs25 Produced in E. coli Delivered with Various Nanoparticles Exhibit Strong Malaria Transmission Blocking Immunity
Plasmodium falciparum Pfs25 Produced in E. coli Delivered with Various Nanoparticles Exhibit Strong Malaria Transmission Blocking Immunity
Masayuki Hayashi,
Mitsubishi Tanabe Pharma, Japan
AdvaxTM, a Formulation of Delta Inulin Microparticles, Is a Non-Canonical Adjuvant that Induces Distinct Immune Response Depending on the Property of Vaccine Antigen
AdvaxTM, a Formulation of Delta Inulin Microparticles, Is a Non-Canonical Adjuvant that Induces Distinct Immune Response Depending on the Property of Vaccine Antigen
Karen Martins,
USAMRIID, USA
Impact of Adjuvants on VLP-Mediated Protection from Ebola Virus Challenge
Impact of Adjuvants on VLP-Mediated Protection from Ebola Virus Challenge
Marie-Ève Lebel,
INRS, Institut Armand Frappier Research Centre, Canada
Plant Virus-Like Nanoparticles as Adjuvant: Mechanisms of Action and Application for Cancer Immunotherapy
Plant Virus-Like Nanoparticles as Adjuvant: Mechanisms of Action and Application for Cancer Immunotherapy
Gokul Swaminathan,
Merck Research Laboratories Cambridge Exploratory Science Center, USA
A Novel Cationic Lipid Nanoparticle Adjuvant Significantly Enhances B Cell and T Cell Responses to Recombinant Sub-Unit Viral Vaccines
A Novel Cationic Lipid Nanoparticle Adjuvant Significantly Enhances B Cell and T Cell Responses to Recombinant Sub-Unit Viral Vaccines
Gervais Rioux,
Université Laval, Canada
Effect of PapMV Adjuvant on the Immune Response Kinetic of Inactivated Flu Vaccine
Effect of PapMV Adjuvant on the Immune Response Kinetic of Inactivated Flu Vaccine
*
Elizabeth A. Leadbetter,
University of Texas Long School of Medicine, USA
Glycolipid Adjuvant-Containing Nanoparticles Protect Against Streptococcus Pneumoniae
Glycolipid Adjuvant-Containing Nanoparticles Protect Against Streptococcus Pneumoniae
14:30—16:30
Workshop 4: Adjuvant Profiling
*
Mario Barro,
Sanofi Pasteur, USA
Adjuvants for Novel and More Efficacious Influenza Vaccines
Adjuvants for Novel and More Efficacious Influenza Vaccines
Christopher B. Fox,
Infectious Disease Research Institute, USA
Benefits and Limitations of in vitro Human Whole Blood and Macrophage Cell Line Assays to Evaluate Activity of Adjuvant Formulations
Benefits and Limitations of in vitro Human Whole Blood and Macrophage Cell Line Assays to Evaluate Activity of Adjuvant Formulations
Wivine Burny,
GlaxoSmithKline, Belgium
Associations between Reactogenicity Symptoms and Parameters of the Early Immune Response to Adjuvanted Vaccines in Humans
Associations between Reactogenicity Symptoms and Parameters of the Early Immune Response to Adjuvanted Vaccines in Humans
Takuo Mizukami,
National Institute of Infectious Diseases, Japan
System Vaccinology Enables to Evaluate the Safety of the Influenza Vaccine and the Adjuvant with a Multiplex Gene Detection System of Novel Biomarkers in the Pre-Clinical Study and Lot Release Test
System Vaccinology Enables to Evaluate the Safety of the Influenza Vaccine and the Adjuvant with a Multiplex Gene Detection System of Novel Biomarkers in the Pre-Clinical Study and Lot Release Test
Jourdan K. Posner,
University of Hawaii, Manoa, USA
The Effect of Possible Vaccine Adjuvants on the Differentiation and Activation of B Cell Subsets Important to the Germinal Center Reaction
The Effect of Possible Vaccine Adjuvants on the Differentiation and Activation of B Cell Subsets Important to the Germinal Center Reaction
Katy M. Graef,
BIO Ventures for Global Health, USA
Accelerating Vaccine Development through Cross-Sector Collaborations
Accelerating Vaccine Development through Cross-Sector Collaborations
Emily Field,
Loyola University Chicago, USA
Developing Adenovirus-Vector Vaccines for MRSA
Developing Adenovirus-Vector Vaccines for MRSA
17:00—19:00
Guiding the Immune Response
Different adjuvants generate different types of immune response. The means by which they do this will be discussed here.
*
Martha A. Alexander-Miller,
Wake Forest University School of Medicine, USA
Kingston H.G. Mills,
Trinity College Dublin, Ireland
TLR-Based Adjuvants for Infectious Disease and Cancer Vaccines - Enhancing Effector Over Regulatory T Cell Responses
TLR-Based Adjuvants for Infectious Disease and Cancer Vaccines - Enhancing Effector Over Regulatory T Cell Responses
Ross M. Kedl,
University of Colorado Denver, USA
T Cell Vaccinology: Lessons Learned in Primates
T Cell Vaccinology: Lessons Learned in Primates
Philippa C. Marrack,
HHMI/National Jewish Health, USA
Host DNA Acts as an Adjuvant in Unexpected Situations
Host DNA Acts as an Adjuvant in Unexpected Situations
Michael Y. Gerner,
NIAID, National Institutes of Health, USA
Short Talk: Strategically Localized Lymph-Sampling Dendritic Cells Promote Rapid T Cell Responses to Particulate Vaccines and Lymph-Borne Pathogens
Short Talk: Strategically Localized Lymph-Sampling Dendritic Cells Promote Rapid T Cell Responses to Particulate Vaccines and Lymph-Borne Pathogens
08:30—12:30
Adjuvants for Still Unmet Needs
Here we will discuss the use of old and new adjuvants in new vaccines.
*
Susan Baldwin,
Infectious Disease Research Institute, USA
Bali Pulendran,
Stanford University School of Medicine, USA
Systems Vaccinology: Enabling Rational Vaccine Design with Systems Biology
Systems Vaccinology: Enabling Rational Vaccine Design with Systems Biology
Lawrence Corey,
Fred Hutchinson Cancer Research Center, USA
Concepts in the Immunotherapy of HSV 2 Infections Role of Adjuvants
Concepts in the Immunotherapy of HSV 2 Infections Role of Adjuvants
Nathalie Garçon,
Bioaster, France
Adjuvants for Vaccines against the Big 3: An Historical Perspective
Adjuvants for Vaccines against the Big 3: An Historical Perspective
Derek T. O'Hagan,
GlaxoSmithKline Vaccines, USA
Can We Design a Single Delivery System for a Broad Range of Molecules from Small Molecule Adjuvants, to Proteins and RNA Vaccines?
Can We Design a Single Delivery System for a Broad Range of Molecules from Small Molecule Adjuvants, to Proteins and RNA Vaccines?
Nitasha R. Bennett,
University of Wisconsin, Madison, USA
Short Talk: Triggering B and T Cell Activation with Synthetic Multivalent Antigens
Short Talk: Triggering B and T Cell Activation with Synthetic Multivalent Antigens
Michael Fichter,
University Medical Center Mainz, Germany
Short Talk: Yeast-Based Expression and Purification of Recombinant Hepatitis C Virus Proteins for the Development of Novel Polymeric Protein Nanovaccines
Short Talk: Yeast-Based Expression and Purification of Recombinant Hepatitis C Virus Proteins for the Development of Novel Polymeric Protein Nanovaccines
14:30—16:30
Workshop 5: Vaccine Mechanisms and Formulations
*
Christopher Jewell,
University of Maryland, USA
Hongming Hu,
Providence Cancer Center, USA
TLR and NALP3 Inflammasome Dependent Innate Immune Responses to Tumor-Derived Autohagosomes (DRibbles)
TLR and NALP3 Inflammasome Dependent Innate Immune Responses to Tumor-Derived Autohagosomes (DRibbles)
Daniel Villarreal,
Advaxis, USA
Immunoadjuvant IL-33 Amplifies Memory CD8 T Cells and Enhances Antigen-Specific Tumor and Viral Immunity
Immunoadjuvant IL-33 Amplifies Memory CD8 T Cells and Enhances Antigen-Specific Tumor and Viral Immunity
*
Arnaud Didierlaurent,
University of Geneva, Switzerland
Early NK Cell Activation as a Result of MPL and QS-21 Combination Controls the Adjuvant effect Induced by the Human Adjuvant System AS01
Early NK Cell Activation as a Result of MPL and QS-21 Combination Controls the Adjuvant effect Induced by the Human Adjuvant System AS01
Iain David Welsby,
Université Libre de Bruxelles, Belgium
Understanding the Cellular and Molecular Mechanisms Involved in the Adjuvanticity of a Liposomal QS-21 Formulation
Understanding the Cellular and Molecular Mechanisms Involved in the Adjuvanticity of a Liposomal QS-21 Formulation
Charlotte Givord,
Université Libre de Bruxelles, Belgium
Deciphering the Signaling Pathways Involved in the Immunostimulatory Properties of the Adjuvant System AS03
Deciphering the Signaling Pathways Involved in the Immunostimulatory Properties of the Adjuvant System AS03
Amy Galliher-Beckley,
Kansas State University, USA
Novel Low-Cost, Easy-to-Use Emulsion Is a Stable Adjuvant and Induces Long-Lasting Antibody Responses to Swine Influenza Virus and Mycoplasma hyopneumoniae
Novel Low-Cost, Easy-to-Use Emulsion Is a Stable Adjuvant and Induces Long-Lasting Antibody Responses to Swine Influenza Virus and Mycoplasma hyopneumoniae
14:30—16:30
Workshop 6: Role of Dendritic Cells in vivo and Dendritic Cell Targeting
*
Ross M. Kedl,
University of Colorado Denver, USA
*
Richard A. Kroczek,
Robert Koch-Institute, Germany
Targeting of Antigen into XCR1+ Dendritic Cells Combined with a Non-Viral Boost Regime Induces Massive CD8+ T Cell Cytotoxicity Capable of Controlling 50xLD50 Listeria Infection and Eradicating Established Tumors
Targeting of Antigen into XCR1+ Dendritic Cells Combined with a Non-Viral Boost Regime Induces Massive CD8+ T Cell Cytotoxicity Capable of Controlling 50xLD50 Listeria Infection and Eradicating Established Tumors
Monica Montes,
Baylor Institute for Immunology Research, USA
Anti-Human CD40 Antibodies with Selective Functional Properties
Anti-Human CD40 Antibodies with Selective Functional Properties
Rossella Cioncada,
University of Siena, Italy
Vaccine Adjuvant MF59 Promotes in vivo Differentiation of Monocyte-Derived Dendritic Cells within Medullary Compartment of the Draining Lymph Nodes, which Correlates with Increased Ability to Trigger T Cell Response
Vaccine Adjuvant MF59 Promotes in vivo Differentiation of Monocyte-Derived Dendritic Cells within Medullary Compartment of the Draining Lymph Nodes, which Correlates with Increased Ability to Trigger T Cell Response
Stefaan De Koker,
University of Gent, Belgium
Inflammatory DCs Constitute a Crucial Source of IL-12 but Fail to Present Antigen in Case of CpG-Adjuvanted Vaccines
Inflammatory DCs Constitute a Crucial Source of IL-12 but Fail to Present Antigen in Case of CpG-Adjuvanted Vaccines
Laura E. Noges,
Fred Hutchinson Cancer Research Center, USA
Host DNA Plays a Role in Generating CD4 T Cell Responses to Various Vaccine Adjuvants
Host DNA Plays a Role in Generating CD4 T Cell Responses to Various Vaccine Adjuvants
Elizabeth A. Thompson,
Karolinska Institute, Sweden
Intravenous Administration of an Agonistic CD40 Antibody Induces Strong T Cell Responses in the Lung
Intravenous Administration of an Agonistic CD40 Antibody Induces Strong T Cell Responses in the Lung
Chinnaswamy Jagannath,
Houston Methodist Research Institute, USA
Induction of Autophagy as an Emerging Molecular Mechanism of Immunoadjvants
Induction of Autophagy as an Emerging Molecular Mechanism of Immunoadjvants
Frédéric Martinon,
CEA - Université Paris-Saclay - Inserm U1184, France
TLR Ligands Indirectly Activate Skin Langerhans Cells by Triggering Local Recruitment of Inflammatory Cells
TLR Ligands Indirectly Activate Skin Langerhans Cells by Triggering Local Recruitment of Inflammatory Cells
14:30—16:30
Workshop 7: Vaccine Delivery
Tarek Hamouda,
NanoBio Corp., USA
Intranasal Nanoemulsion-Adjuvanted Genital Herpes Vaccine; A New Approach Utilizing Mucosal Immunity to Induce Protection Against HSV2 Infections
Intranasal Nanoemulsion-Adjuvanted Genital Herpes Vaccine; A New Approach Utilizing Mucosal Immunity to Induce Protection Against HSV2 Infections
*
Olivia M. Flynn,
University College Cork, Ireland
Immunogenicity of dmLT Adjuvanted Vaccines in ImmuPatch Dissolvable Microneedle Patches in Mice
Immunogenicity of dmLT Adjuvanted Vaccines in ImmuPatch Dissolvable Microneedle Patches in Mice
Chintan Hareshbhai Kapadia,
University of North Carolina at Chapel Hill, USA
PRINT Nanoparticulate Subunit Vaccine to Combat Cancer
PRINT Nanoparticulate Subunit Vaccine to Combat Cancer
Sudhir Pai Kasturi,
Emory University, USA
Programming the Magnitude and Persistence of Humoral Immunity Against HIV Using Novel TLR Ligands Delivered in Biodegradable Nanoparticles
Programming the Magnitude and Persistence of Humoral Immunity Against HIV Using Novel TLR Ligands Delivered in Biodegradable Nanoparticles
Kouji Kobiyama,
National Institute of Biomedical Innovation, Japan
K3-SPG, a Nano-Particulate TLR9 Agonistic Ligand Works as a Potent IFN Inducer and CTL Adjuvant
K3-SPG, a Nano-Particulate TLR9 Agonistic Ligand Works as a Potent IFN Inducer and CTL Adjuvant
*
Aaron Palmer Esser-Kahn,
University of California, Irvine, USA
Controlling Adjuvant Activity with Light
Controlling Adjuvant Activity with Light
17:00—18:30
New Approaches to Vaccines
*
Laura Shackelton,
Bill & Melinda Gates Foundation, USA
Jenny P.Y. Ting,
University of North Carolina at Chapel Hill, USA
Impact of NLR Proteins on Innate and Adaptive Immunity
Impact of NLR Proteins on Innate and Adaptive Immunity
Robert A. Seder,
NIAID, National Institutes of Health, USA
Adjuvants for HIV Vaccines, Mice versus Humans
Adjuvants for HIV Vaccines, Mice versus Humans
*Session Chair †Invited, not yet responded.
Keystone Symposia thanks our Sponsors(s) for generously supporting this meeting:
|
|
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
